Announcements Trials
Browse Landscape

Phase

Phase 1 3Phase NA 1

Status

Terminated 3Recruiting 3Active not recruiting 3Completed 2

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 2

Conditions

Carcinoma, Non-Small-Cell Lung 102Breast Neoplasms 80Neoplasms 72Melanoma 63Neoplasm Metastasis 62Leukemia, Myeloid, Acute 58Ovarian Neoplasms 54Lymphoma, Non-Hodgkin 53Multiple Myeloma 51Prostatic Neoplasms 50Colorectal Neoplasms 50Glioblastoma 48Pancreatic Neoplasms 47Lung Neoplasms 45Recurrence 42Carcinoma, Renal Cell 40Squamous Cell Carcinoma of Head and Neck 37Leukemia, Lymphocytic, Chronic, B-Cell 37Triple Negative Breast Neoplasms 35Myelodysplastic Syndromes 30Lymphoma, Large B-Cell, Diffuse 28Glioma 28Stomach Neoplasms 27Precursor Cell Lymphoblastic Leukemia-Lymphoma 27Lymphoma, B-Cell 27Brain Neoplasms 27Lymphoma, Follicular 26Endometrial Neoplasms 26Lymphoma 25Carcinoma, Hepatocellular 24

Interventions

pembrolizumab 1durvalumab 1dostarlimab 1atezolizumab 1Etoposide 1Carboplatin 1AMG 757 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1 × Active not recruiting × Bites and Stings × Clear all
NCT05361395 2026-03-03

First-Line Tarlatamab in Combination With Carboplatin, Etoposide, and PD-L1 Inhibitor in Subjects With Extensive Stage Small Cell Lung Cancer (ES-SCLC)

Amgen

Phase 1 Active not recruiting
184 enrolled
Thoracic

Bites and Stings, Lung Neoplasms

NCT03843359 2026-01-08

A First Time in Human (FTIH) Study of GSK3745417 Administered to Participants With Advanced Solid Tumors

GlaxoSmithKline

Phase 1 Active not recruiting
97 enrolled 45 charts

Bites and Stings, Neoplasms

NCT03319940 2025-11-19

Study Evaluating Safety, Tolerability and Pharmacokinetics (PK) of Tarlatamab in Adults With Small Cell Lung Cancer (SCLC)

Amgen

Phase 1 Active not recruiting
269 enrolled
Thoracic

Bites and Stings, Neoplasms, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡